RXRX Recursion Pharmaceuticals

• None no insider bought on the open market
• None no sales outside a trading plan
• $8.2M sold by 6 insiders under 10b5-1 plans

1. Insider
   Trade
   Value
   Traded, filed
2. Blake Borgeson Director
   Planned sale
   $242K 50,000 shares at $4.84 0.8% of stake
   Traded Oct 6 Filed Oct 7
   ↗
3. Robert Hershberg Director
   Planned sale
   $125K 25,000 shares at $5.00 13% of stake
   Traded Oct 6 Filed Oct 7
   ↗
4. Najat Khan CEO
   Planned sale
   $79K 22,408 shares at $3.52 1.1% of stake
   Traded Sep 8 Filed Sep 10
   ↗
5. Blake Borgeson Director
   Planned sale
   $100K 30,000 shares at $3.34 0.5% of stake
   Traded Sep 1 Filed Sep 2
   ↗
6. Blake Borgeson Director
   Planned sale
   $98K 30,000 shares at $3.25 0.5% of stake
   Traded Aug 4 Filed Aug 6
   ↗
7. Blake Borgeson Director
   Planned sale
   $159K 40,000 shares at $3.96 0.6% of stake
   Traded Jul 7 Filed Jul 9
   ↗
8. Namandje Bumpus Director
   Planned sale
   $13K 3,963 shares at $3.18 3% of stake
   Traded Jun 18 Filed Jun 22
   ↗
9. Najat Khan CEO
   Planned sale
   $84K 23,588 shares at $3.58 1.1% of stake
   Traded Jun 5 Filed Jun 5
   ↗
10. Christopher Gibson Director
    Planned sale
    $145K 40,000 shares at $3.62 4.3% of stake
    Traded Jun 5 Filed Jun 5
    ↗
11. Namandje Bumpus Director
    Planned sale
    $16K 4,386 shares at $3.54 9.2% of stake
    Traded Jun 3 Filed Jun 4
    ↗
12. Blake Borgeson Director
    Planned sale
    $110K 30,000 shares at $3.68 0.5% of stake
    Traded Jun 2 Filed Jun 4
    ↗
13. Christopher Gibson Director
    Planned sale
    $123K 40,000 shares at $3.08 4.3% of stake
    Traded May 22 Filed May 27
    ↗
14. Christopher Gibson Director
    Planned sale
    $135K 40,000 shares at $3.37 4.1% of stake
    Traded May 7 Filed May 8
    ↗
15. Blake Borgeson Director
    Planned sale
    $106K 30,000 shares at $3.52 0.5% of stake
    Traded May 5 Filed May 7
    ↗
16. Christopher Gibson Director
    Planned sale
    $144K 40,000 shares at $3.61 4.2% of stake
    Traded Apr 22 Filed Apr 24
    ↗

Also filed in the last 12 months, not counted as buying or selling: 24 share withholdings for taxes, 23 stock grants, 16 conversions, 5 gifts, and 1 option exercise.